Company: Biomemory
CEO: Laurent Guengant
Website: https://www.biomemory.com/
About Biomemory
Biomemory was founded in 2021 in Paris, emerging from years of research at Sorbonne University and CNRS. The company builds DNA-based data storage, encoding digital information into synthetic DNA to deliver retention and readability for up to 150 years. Biomemory owns the full molecular stack, from biology to hardware to enterprise software, a rare integration in this emerging industry.
One of the biggest challenges the team overcame was industrialising a laboratory technique into a repeatable, IT-compatible product. Turning DNA synthesis and DNA reading into an end-to-end system, from digital file ingestion to encoding, storage, and reliable retrieval, required years of cross-disciplinary work across biochemistry, hardware, and software engineering. Biomemory is among the first companies in the DNA data storage industry to reach this level of industrial readiness.
In March 2026, Biomemory acquired the assets of Catalog Technologies, a Boston-based pioneer in DNA data storage and computing that had ceased operations. Rather than letting this deep American research and intellectual property disappear, Biomemory brought it in-house and opened a flagship Research and Development and Production hub in Boston. The Boston site now houses a laboratory, dedicated production units, and technical customer support, staffed in part by former Catalog experts. This hub anchors Biomemory in the United States and serves as the launch pad for its North American go-to-market strategy.
The impact on the US ecosystem is direct: Biomemory preserved specialised DNA storage jobs and know-how in Massachusetts that might otherwise have been lost when Catalog wound down, and it is now growing that team as part of a global company. The acquisition also combined many patents spanning encoding, synthesis, storage, retrieval, search, and computing, strengthening the intellectual property base tied to US operations. Biomemory is building toward commercial deployment of DNA storage inside data centres, aiming to give US enterprises and institutions a secure, durable, and energy-efficient alternative to traditional storage media for their most sensitive and long-lived data.
Beyond Boston, Biomemory is a leader in commercial DNA data storage and co-chairs the DNA Data Storage Alliance, working alongside US and international peers to advance standards for this new category. The company raised an 18 million dollar Series A round in December 2024 to fund its molecular platform, and it is now working toward commercial launch milestones targeted for the second half of 2026. With owned production now split between Paris and Boston, Biomemory is positioning DNA as a sovereign, long-term information tier for organisations across the US and Europe that need to protect their most critical, irreplaceable data for decades.
Want to find out what TechRound can do for your business?
